浙江国资系资本入局！灵巧手与神经接口研发商「傲意科技」完成近亿元B++轮融资！

Core Viewpoint - Aoyi Technology, a developer of dexterous hands and neural interfaces, has successfully completed a B++ round of financing, raising nearly 100 million yuan to accelerate R&D and product launches in key areas [1][14]. Group 1: Financing and Growth - The recent financing round was led by Infiniti Capital, Zhejiang State-owned Capital Operation Co., and Womeda Capital, with Shengke Capital serving as the long-term financial advisor [1]. - This funding will support the development of dexterous hand technology, the launch of new products, and the establishment of a standardized production system aimed at doubling annual production capacity [1][14]. - Prior to this round, Aoyi Technology completed a B+ round of financing just over three months ago, indicating strong growth momentum and continued appeal in the capital market [14]. Group 2: Company Overview - Aoyi Technology, founded in 2015 in Shanghai Zhangjiang Hi-Tech Park, is one of the few companies in China that integrates core technologies in brain-machine interfaces and robotics [1]. - The company has developed a self-research platform that combines neural interfaces, robotics, and AI algorithms [1]. Group 3: Product Development and Market Position - Aoyi Technology has successfully developed multiple innovative products over nearly a decade, achieving recognition in the global market for their performance and cost-effectiveness [4]. - The company is one of the earliest teams in China to focus on dexterous robots, with its first dexterous hand product receiving positive feedback from various clients [4][5]. - Aoyi Technology has built a strong production and delivery capability, positioning itself as a key player in the dexterous hand market [5]. - The upcoming ROH-AP001 dexterous hand will integrate tactile and pressure sensing capabilities, expected to launch soon [5]. Group 4: Technological Advancements - Aoyi Technology has developed a medical-grade neural interaction platform based on its proprietary brain/muscle interface technology, holding over 80 patents [8]. - The OHand™ series of smart bionic hands has rapidly gained market share since its launch in 2020, achieving FDA/CE certification and initiating overseas commercialization in 2024 [8].